(Q44215065)

30 November 2017

title

Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs (English)

1 reference

30 November 2017

0 references

1 reference

7

L Hammarström

1 reference

30 November 2017

A Gardulf

1

1 reference

30 November 2017

V Andersen

2

1 reference

30 November 2017

J Björkander

3

1 reference

30 November 2017

D Ericson

4

1 reference

30 November 2017

S S Frøland

5

1 reference

30 November 2017

R Gustafson

6

1 reference

30 November 2017

M B Jacobsen

8

1 reference

30 November 2017

E Jonsson

9

1 reference

30 November 2017

G Möller

10

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 February 1995

1 reference

30 November 2017

1 reference

30 November 2017

volume

345

1 reference

30 November 2017

issue

8946

1 reference

30 November 2017

page(s)

365-369

1 reference

Home intravenous immunoglobulin therapy by self-administration

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Self-infusion of intravenous immunoglobulin by immunodeficient patients at home

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Immunoglobulin replacement therapy by slow subcutaneous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Slow subcutaneous immunoglobulin therapy in a patient with reactions to intramuscular immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Subcutaneous infusion of gammaglobulins in management of agammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Rapid subcutaneous immunoglobulin infusions in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Subcutaneous immunoglobulin home treatment in hypogammaglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Itching for an explanation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Hepatitis C virus transmission by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

Ciprofloxacin in a case of Q fever endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2895%2990346-1

7 January 2021

10.1016/S0140-6736(95)90346-1

Identifiers

DOI

1 reference

30 November 2017

1 reference